Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell LymphomaAustin I. Kim, Mark A. Murakami, Lisa Brennan et al.|Blood|2023Cited by 6
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)Austin Kim, Mark A. Murakami, Peter A. Riedell et al.|Blood|2025Cited by 4
Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)Austin I. Kim, Mark A. Murakami, Philippe Armand et al.|Blood|2024Cited by 2